AMRI Awarded API Contract

News
Article

AMRI has been awarded a seven-year contract for an active ingredient under clinical evaluation.

AMRI reported that its subsidiary, Albany Molecular Research, located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation by the Defense Science and Technology Laboratory, acting on behalf of the United Kingdom’s Secretary of State for Defense, the Department of National Defense of Canada, and Minister of Defense of the Kingdom of the Netherlands.

AMRI will initially work on the development and scale-up of the investigational drug, and the manufacture and supply for use during Phase I clinical trials. If the trials are successful, AMRI could become the commercial manufacturer of the product for distribution to the government partners of this contract, including the UK, the Netherlands, and Canada.

Source: AMRI

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content